Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat-containing and planar cell polarity effector protein (WDPCP) is a cytoplasmic WD40 repeat protein that acts as a key effector in the planar cell polarity (PCP) signaling pathway and is essential for ciliogenesis[1][2][3][5][6]. It plays a central role in organizing the cytoskeleton—particularly regulating septin localization—and controls both cilia formation and collective cell movements[1][3][5]. WDPCP is also required for maintaining the stability of the epithelial cell cortex and plasma membrane via interactions with septins and actomyosin[3][5]. Mutations in WDPCP are implicated in Bardet-Biedl syndrome type 15, Meckel-Gruber syndrome, and are associated with ciliary dysfunction in other settings such as chronic rhinosinusitis[1][2][3][5][6]. Despite its crucial developmental and structural cellular roles, it is not currently considered a direct therapeutic target or drugged protein[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD repeat-containing and planar cell polarity effector protein (WDPCP).